PUBLISHER: DelveInsight | PRODUCT CODE: 1378000
PUBLISHER: DelveInsight | PRODUCT CODE: 1378000
“"CNTX-4975 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CNTX-4975 for osteoarthritis in the six major markets. A detailed picture of the CNTX-4975 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the CNTX-4975 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNTX-4975 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
Centrexion Therapeutics' lead product candidate, CNTX-4975, is being evaluated for the treatment of moderate to severe pain of knee OA. CNTX-4975 is an ultra-pure, synthetic form of trans-capsaicin injected directly into the pain site. It harnesses the natural analgesic power of capsaicin to develop a proprietary injectable therapy designed to provide fast-acting, durable and targeted pain relief.
The TRPV1 receptor that selectively inactivates local pain fibers transmitting pain signals to the brain is targeted by CNTX-4975, potentially providing relief that can last up to 6 months until local pain fibers are regenerated. CNTX-4975 manages pain without disrupting other nerve functions through its targeted delivery and highly-selective method of action.
Additionally, three Phase III clinical trials, namely VICTORY-1, VICTORY-2, and VICTORY-3 studies, are in progress for CNTX-4975 examining capsaicin and its potential to provide extended relief from knee OA. Apart from that, the company is also evaluating the other product CNTX-6970 (CCR2 antagonist) in Phase IIa for OA pain.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CNTX-4975 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of CNTX-4975 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of CNTX-4975 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions